Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine.

Machine translation Machine translation
类别 Primary study
期刊Rheumatology (Oxford, England)
Year 1999
連結 Pubmed
目的：确定是否与硫嘌呤甲基转移酶（TPMT）的减少或缺如活动相关基因多态性的存在，参与硫唑嘌呤代谢酶，可以预测的副作用，尤其是骨髓抑制，在服用此药的病人。 方法：TPMT基因型120例确定系统性红斑狼疮（SLE），连同15例炎症性肠病（IBD）和临床暴露硫唑嘌呤的影响密切相关。 结果：TPMT多态性名患者进行检测。严重的骨髓毒性发生中所确定的单一纯合子。硫唑嘌呤一般耐受性良好，但检测到11药物相关neutropenias。在只有11例之一是确定了TPMT的多态性。 结论：纯合子TPMT缺乏症与严重骨髓抑制有关。在大多数情况下，然而，TPMT基因型分型之前，硫唑嘌呤治疗不会有预测的骨髓抑制的事件，并且可以增加，但不能替换，定期血液监测。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 43960cae568b64b87095da6e7c9c2159d6840d33
First added on: Oct 01, 2013
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use